Low Dose Radiotherapy Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Stage II-III NSCLC

To evaluate efficacy and safety of low dose radiotherapy combined with sintilimab and platinum based chemotherapy as neoadjuvant therapy for stage II-III Non-Small Cell Lung Cancer

Trial Details

NCT ID
NCT06714708
Phase
PHASE2
Sponsor
Anhui Provincial Cancer Hospital
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Experimental
  • Active comparator
Locations (sample)
  • Hefei, Anhui, China|31.86389,117.28083

Key Eligibility Criteria

  • Patients who meet all of the following inclusion criteria are eligible for inclusion in this study:
  • Sign a written Informed Consent Form (ICF) and be able to comply with the visit and related procedures specified in the protocol.
  • Age ≥ 18 years old.
  • Primary non-small cell lung cancer (including adenocarcinoma and squamous cell carcinoma) diagnosed by cytology or histology.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →